siRASA1 in vascular endothelial cells alleviates subretinal fibrosis through inhibiting macrophage-myofibroblast transdifferentiation via SHH signaling pathway
Cellular Signalling · 2026
DOI: 10.1016/j.cellsig.2025.112261 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cellular Signalling, 2026. Verfasst von Lei Jiang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China. Hauptthemen laut MEDLINE: Hedgehog Proteins, Cell Transdifferentiation, Macrophages, Myofibroblasts. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Key Research and Development Program of China.
Abstract (Originalsprache)
Subretinal fibrosis (SRF) is a vision-threatening complication of neovascular age-related macular degeneration (nAMD) driven by angiogenesis, inflammation, and collagen deposition,which is refractory to current anti-VEGF treatments. This study investigates the role of RASA1 in promoting SRF through Sonic Hedgehog (SHH) signaling. We found that VEGF stimulation upregulates RASA1 in human umbilical vein endothelial cells (HUVECs), potentiating the secretion of SHH. Secreted SHH then activates the SHH-SMO/PTCH1-GLI1 axis in macrophages, driving their transdifferentiation into myofibroblasts and promoting fibrogenesis. Furthermore, a positive feedback loop was identified: macrophage-derived EFNB2 activated EphB4-RASA1 in HUVECs, exacerbating fibrosis. To therapeutically disrupt this circuit, we engineered a multifunctional nanoparticle system, MGPDA@Eylea/siRASA1, for the co-delivery of siRASA1 and the anti-VEGF drug Eylea. This nanotherapeutic demonstrated excellent biocompatibility and effectively attenuated the fibrotic cascade by suppressing RASA1 expression, inhibiting SHH signaling, and mitigating macrophage-to-myofibroblast transition (MMT), thereby delaying SRF progression. Our work unveils a previously unrecognized intercellular circuit driving fibrosis and presents a promising nanomedicine-based strategy for managing fibrotic complications in nAMD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
- Department of Ophthalmology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China; Department of Ophthalmology, the Third People's Hospital of Bengbu, Bengbu, China. Electronic addres…
- Department of Ophthalmology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China; Department of Ophthalmology, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shang…
Förderung
- National Key Research and Development Program of China
Zitieren
APA
Jiang, L., Xu, Z., Ma, J., Cai, W., Lin, R., Hu, C., Luo, Y., Liang, F., Wu, Y., & Yu, J. (2026). siRASA1 in vascular endothelial cells alleviates subretinal fibrosis through inhibiting macrophage-myofibroblast transdifferentiation via SHH signaling pathway. Cellular Signalling. https://doi.org/10.1016/j.cellsig.2025.112261
Vancouver
Jiang L, Xu Z, Ma J, Cai W, Lin R, Hu C, et al. siRASA1 in vascular endothelial cells alleviates subretinal fibrosis through inhibiting macrophage-myofibroblast transdifferentiation via SHH signaling pathway. Cellular Signalling. 2026. doi:10.1016/j.cellsig.2025.112261
BibTeX
@article{Jiang2026,
author = {Jiang, Lei and Xu, Zihang and Ma, Jingyang and Cai, Wenting and Lin, Ruoyi and Hu, Chengyu and Luo, Yunhong and Liang, Feng and Wu, Yan and Yu, Jing},
title = {siRASA1 in vascular endothelial cells alleviates subretinal fibrosis through inhibiting macrophage-myofibroblast transdifferentiation via SHH signaling pathway},
journal = {Cellular Signalling},
year = {2026},
doi = {10.1016/j.cellsig.2025.112261}
}
EUVIMED